Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Participants will be randomized to a single application sequence, either sequence "A" (intranasal application followed by control application) or sequence "B" (control application followed by intranasal application) using the device. Upon entering the CAE, participants will complete dry eye questionnaires every five minutes and will administer the device either intranasally or extranasally in randomized sequence when a certain level of ocular discomfort has been reached.
Age
22–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Moderate to severe dry eye disease
Normal lid/lash anatomy, blinking function and closure as determined by the Investigator
Literate, able to speak English, and able to complete questionnaires independently
You may not be if
Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the Investigator, may lead to risk of clinically significant increased bleeding
Nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas
Implanted metallic or electronic device in the head, a cardiac demand pacemaker, or an implanted defibrillator
Corneal transplant in either or both eyes
A woman who is pregnant, nursing an infant, or planning a pregnancy at the Screening Visit
Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to the Screening Visit